AstraZeneca PLC (LON:AZN – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of £134.38 and traded as low as £132.74. AstraZeneca shares last traded at £133.09, with a volume of 1,706,220 shares traded.
Analysts Set New Price Targets
AZN has been the subject of several recent research reports. Deutsche Bank lifted their price target on AstraZeneca from £117 to £120 and gave the company a “hold” rating in a research report on Friday, November 6th. Berenberg Bank reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a report on Wednesday, October 7th. Jefferies Financial Group reissued a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday. Citigroup boosted their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Finally, Royal Bank Of Canada started coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating and a £145 target price on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average target price of £155.50.
Read Our Latest Stock Analysis on AZN
AstraZeneca Price Performance
Insider Buying and Selling
In other news, insider Michel Demare acquired 2,500 shares of the stock in a transaction dated Monday, September 14th. The stock was purchased at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is owned by corporate insiders.
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Read More
- Five stocks we like better than AstraZeneca
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
